Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P01772
UPID:
HV333_HUMAN
Alternative names:
Ig heavy chain V-III region HIL; Ig heavy chain V-III region KOL
Alternative UPACC:
P01772; A0A0B4J1V3; P01771
Background:
Immunoglobulin heavy variable 3-33, known as Ig heavy chain V-III region HIL or KOL, plays a crucial role in the immune response. It forms part of the variable domain of immunoglobulin heavy chains, engaging in antigen recognition. This protein is pivotal in humoral immunity, facilitating the recognition, clonal expansion, and differentiation of B lymphocytes into plasma cells, which secrete antibodies to eliminate antigens.
Therapeutic significance:
Understanding the role of Immunoglobulin heavy variable 3-33 could open doors to potential therapeutic strategies. Its involvement in antigen recognition and the immune response highlights its significance in developing treatments for immune-related disorders.